FUSION ANTIBODIES PLC Logo

FUSION ANTIBODIES PLC

A CRO providing end-to-end antibody engineering services for therapeutic & diagnostic development.

FAB | IL

Overview

Corporate Details

ISIN(s):
GB00BDQZGK16
LEI:
213800KBAYRC9VOQ9V39
Country:
United Kingdom
Address:
1 SPRINGBANK ROAD, BT17 0QL BELFAST
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive range of antibody engineering services for therapeutic and diagnostic development. Established in 2001, the company functions as an end-to-end R&D partner, guiding projects from initial antigen design through discovery, engineering, and supply, to pre-clinical cell line development. Its core services include antibody generation, production, characterization, and optimization. Fusion Antibodies emphasizes a collaborative approach, working as an extension of its clients' teams to deliver biologics optimized for long-term manufacturability and commercialization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-25 13:25
Major Shareholding Notification
Holding(s) in Company
English 21.0 KB
2025-11-24 08:15
Interim Report
Half-year Financial Report
English 225.3 KB
2025-11-21 08:25
Report Publication Announcement
Notice of Results
English 17.0 KB
2025-11-13 08:30
Regulatory News Service
OptiMAL Library video
English 16.9 KB
2025-11-03 08:20
Regulatory News Service
OptiMAL® R&D Update
English 16.5 KB
2025-10-27 16:38
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-10-16 14:31
Post-Annual General Meeting Information
Result of AGM
English 15.7 KB
2025-10-16 08:00
Post-Annual General Meeting Information
AGM statement and H1 trading update
English 17.4 KB
2025-09-19 13:58
Report Publication Announcement
Posting of Annual Report & Notice of AGM
English 14.2 KB
2025-09-17 08:00
Regulatory News Service
OptiMAL R&D Update
English 21.3 KB
2025-09-08 08:00
Report Publication Announcement
Belfast investor presentation
English 15.2 KB
2025-09-04 08:00
Earnings Release
Final Results
English 439.7 KB
2025-07-24 11:56
Legal Proceedings Report
Issue Notification: US Patent Update
English 14.4 KB
2025-07-11 08:00
Director's Dealing
Director/PDMR Shareholding
English 24.7 KB
2025-06-02 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 14.0 KB

Automate Your Workflow. Get a real-time feed of all FUSION ANTIBODIES PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FUSION ANTIBODIES PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for FUSION ANTIBODIES PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sweden
MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland
MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland
MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany
MOR
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom
N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel
NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France
COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom
ONC
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden
ONCOZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.